Anticoagulant-free preparation of autologous platelet-rich plasma (PRP) / fluid platelet-rich fibrin (f-PRF): a pre-clinical comparative performance study.

OBJECTIVE

This study aimed to validate and characterize the efficacy of a previously developed anticoagulant-free, single soft-spin centrifugation device for the preparation of autologous fluid-Platelet-Rich Fibrin (f-PRF).

INTRODUCTION

f-PRF is generated via one-step soft-spin centrifugation of all blood to produce a platelet-enriched plasma for regenerative medicine use, without the need for additional chemical agents. This study validated the performance of a novel single soft-spin f-PRF preparation system.

METHODS

Sixteen healthy volunteers (94% female, ages 23-52) donated blood for a comparative analysis between Exprecell™ and Arthrex ACP® Double-Syringe systems. f-PRF was prepared using standardized centrifugation (420xg, 5 min) and characterized for cellular composition, platelet function, growth factors, and extracellular vesicles (EVs). Platelet activation was assessed via P-selectin expression and GPIIb/IIIa activation following stimulation using flow cytometry.

RESULTS

Exprecell™ yielded 20% more f-PRF volume (6.5-10.5 vs. 5.5-9.0 mL) with excellent cellular depletion (>99% erythrocyte, >95% leukocyte reduction). Platelet counts and function were similar between systems, with preserved in vitro agonist responses in terms of P-selectin expression and GPIIb/IIIa activation. Most growth factors remained below detection limits, and those detectable showed no differences between the devices. EV profiles from different cell types were also comparable.

CONCLUSION

These findings support the Exprecell™ single soft-spin methodology, demonstrating that anticoagulant-free f-PRF preparation achieves functional equivalence to conventional methods while providing a statistically significant increase in volume yield and procedural simplicity. The closed system design reduces contamination risk and Luer-lock compatibility facilitates integration into clinical workflows. Maintained in vitro biological activity supports clinical utility for this innovative point-of-care f-PRF preparation device. Future studies are needed to demonstrate the clinical benefit of the f-PRF obtained.